Serina Therapeutics ( (SER) ) has provided an update.
On February 3, 2025, Serina Therapeutics announced the completion of a second $5 million tranche of a $10 million financing deal with JuvVentures, supporting the progression of SER-252 into Phase 1 clinical trials for advanced Parkinson’s disease in late 2025. This capital injection, achieved by issuing shares at a 113% premium, underlines Serina’s commitment to its innovative drug delivery platform and enhances its market positioning by potentially offering significant benefits in Parkinson’s treatment.
More about Serina Therapeutics
Serina Therapeutics is a clinical-stage biotechnology company headquartered in Huntsville, Alabama, focused on developing treatments for neurological diseases and other conditions. Utilizing its proprietary POZ Platform™, Serina aims to enhance the efficacy and safety of various therapeutics, including small molecules and antibody-based drug conjugates, and has partnerships for expanding its technology’s applications.
YTD Price Performance: -7.84%
Average Trading Volume: 27,773
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $41.79M
See more data about SER stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com